FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Beyond Air, Inc. Stock AnalysisComprehensive stock analysis for Beyond Air, Inc. (XAIR) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisXAIR
XAIR
Beyond Air, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
XAIR
Home🔹Stocks🔹Beyond Air, Inc.

Beyond Air, Inc.

🇺🇸XAIR•NASDAQ

Beyond Air, Inc.

🇺🇸XAIR•NASDAQ
Market cap
$2.31M
Sentiment

Your view on XAIR

Mkt Cap
$2.31M
Sentiment
Your view
XAIR
Beyond Air, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
XAIR
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Beyond Air, Inc.

Industry
Medical - Devices
Sector
Healthcare
CEO
Steven Adam Lisi
Headquarters
900 Stewart Avenue, Garden City, NY, US
Industry
Medical - Devices
Sector
Healthcare
CEO
Steven Adam Lisi
Headquarters
900 Stewart Avenue, Garden City, NY, US
Description

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.

The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria.

The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Beyond Air, Inc., and the rating behind it. XAIR last traded at $3.20; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Beyond Air, Inc.. Starting points for Beyond Air, Inc.: EPS -$46.43, beta 0.15 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Beyond Air, Inc.. Beyond Air, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Beyond Air, Inc.. Trailing twelve-month EPS for Beyond Air, Inc. stands at -$46.43. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Beyond Air, Inc.. Beyond Air, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Beyond Air, Inc. valued side by side against its closest peers. Beyond Air, Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Beyond Air, Inc., and how their positions are changing. At a $2.3M market value, institutional positions materially move Beyond Air, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Beyond Air, Inc. executives and directors. Shares of Beyond Air, Inc. have traded between $1.29 and $13.52 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Beyond Air, Inc.. Beyond Air, Inc. is a $2.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Beyond Air, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Beyond Air, Inc.. Coverage tracks Beyond Air, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • AEON — AEON Biopharma, Inc.
  • BOLT — Bolt Biotherapeutics, Inc.
  • CLRB — Cellectar Biosciences, Inc.
  • CODX — Co-Diagnostics, Inc.
  • LFWD — Lifeward Ltd.
  • LYRA — Lyra Therapeutics, Inc.
  • SINT — Sintx Technologies, Inc.

More Medical - Devices companies

  • ARX.AX — Aroa Biosurgery Limited
  • ASAPF — Aurora Spine Corporation
  • ASG.V — Aurora Spine Corporation
  • ASTI.CN — Aquarius Surgical Technologies Inc.
  • AT1.AX — Atomo Diagnostics Limited
  • ATEC — Alphatec Holdings, Inc.
  • AVH.AX — AVITA Medical, Inc.
  • AVHHL — AVITA Medical, Inc.
  • AVR — Anteris Technologies Global Corp.
  • AVR.AX — Anteris Technologies Ltd
  • AXGN — AxoGen, Inc.
  • BBNX — Beta Bionics, Inc.

ETFs holding Beyond Air, Inc.

  • VXF — Vanguard Extended Market ETF (0.00%)

News

Latest Market News